ผู้วิจัย/Authors: Kiran Haridas, Naveen Chauhan, Indrani Poddar, Keshava Pai.

ชื่อเรื่อง/Title: Randomized Study to Compare the Efficacy and Tolerability of Escitaropram and Duloxetine in Subject with Major Depressive Disorder.

แหล่งที่มา/Source: ASEAN Journal of Psychiatry. Vol. 9, Supplement 1, 26-29 August 2008, page 43.

รายละเอียด / Details:

Objective : Management of depression presents a significant medical challenge, and there is a need for further clinical trials. The authors compared the efficacy and tolerability between escitaropram and duloxetine in patients with major depressive disorder (MDD). Methods : This was a 12 weeks randomized open study of comparison of efficacy and tolerability between escitaropram (10-20mg/day) and duloxetine (40-60mg/day) in patients with MDD. The prospectively defined primary efficacy parameters were the change from baseline in mean Hamilton rating scale for depression (HAMD17) total score at end point using last observation carried forward. Results : In the present study, the primary analysis detected a statistically significant difference between escitaropram and duloxetine in response rate, remission rate and tolerability. There was no statistically significant difference detected in efficacy of onset. Response rate, remission rate and efficacy of onset were highly significant within the duloxetine group. There were a few side effects that were mild and self limiting. Nausea was the most common side effect present in 8.3% at visit 3 (30 days) and 8.3% at visit 5 (60 days) with duloxetine and escitalopram, respectively. Anorexia was seen 8.3% of people at visit 4 (45 days) with escitalopram. Insomnia troubled in 8.3% of patients at visit 4 (45 days) and 5 (60 days) with duloxetine and escitalopram, respectively. Headache was seen in 8.3% of the patients with duloxetine at visit 5 (60 days). No organ damage was detected. Conclusion : Both escitalopram and duloxetine were well tolerated mulecules at comparable doses. Duloxetine is superior to escitalopram in response and remission of treatment of MDD in similar clinical settings and thus can be preferred.

Keywords: randomized study, compare, efficacy, tolerability, escitalopram, duloxetine, depressive disorder

ปีที่เผยแพร่/Year: 2008

Address: Department of Pharmacology, Kasturba Medical College, Manipal University, India

Code: 2010000296

ISSN/ISBN: 0218-3420

Country of publication: Thailand

Language: English

Category: Abstract

Download: